Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta‐analysis C Campbell, T Wang, AL McNaughton, E Barnes, PC Matthews Journal of viral hepatitis 28 (3), 493-507, 2021 | 65 | 2021 |
Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following tocilizumab therapy: a systematic review to inform … C Campbell, MI Andersson, MA Ansari, O Moswela, SA Misbah, ... Frontiers in Medicine, 1346, 2021 | 34 | 2021 |
Acute Severe Hepatitis Outbreak in Children: A Perfect Storm What do we know, and what questions remain? PC Matthews, C Campbell, A Rivero-Juarez, BJ Van Welzen, BK Tan, ... Frontiers in Pharmacology, 4909, 2022 | 21 | 2022 |
Impaired humoral and cellular response to primary COVID‐19 vaccination in patients less than 2 years after allogeneic bone marrow transplant SM Murray, M Barbanti, C Campbell, A Brown, L Chen, J Dhanapal, ... British Journal of Haematology 198 (4), 668-679, 2022 | 17 | 2022 |
Evaluation of disruptive camouflage of avian cup‐nests T Mulder, CJ Campbell, GD Ruxton Ibis 163 (1), 150-158, 2021 | 15 | 2021 |
Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study T Wang, DA Smith, C Campbell, J Mokaya, O Freeman, H Salih, ... BMC infectious diseases 21 (1), 1-14, 2021 | 12 | 2021 |
Cohort Profile: National Institute for Health Research Health Informatics Collaborative: Hepatitis B Virus (NIHR HIC HBV) Research Dataset T Wang, DA Smith, C Campbell, O Freeman, Z Moysova, T Noble, ... International Journal of Epidemiology, 1-11, 2022 | 9 | 2022 |
Longitudinal analysis of the utility of liver biochemistry as prognostic markers in hospitalized patients with corona virus disease 2019 T Wang, DA Smith, C Campbell, S Harris, H Salih, KA Várnai, K Woods, ... Hepatology Communications 5 (9), 1586-1604, 2021 | 9 | 2021 |
Estimating the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we know and what are we missing?[version 1; peer review: 1 approved, 2 approved with … C Campbell, T Wang, R Burrow, S Mandal, J Hippisley-Cox, E Barnes, ... Wellcome Open Research 7, 2022 | 8 | 2022 |
A systematic review of Hepatitis B virus (HBV) prevalence and genotypes in Kenya: Data to inform clinical care and health policy LO Downs, C Campbell, P Yonga, MA Ansari, PC Matthews, AO Etyang medRxiv, 2022 | 7 | 2022 |
Development and validation of personalised risk prediction models for early detection and diagnosis of primary liver cancer among the English primary care population using the … W Liao, P Jepsen, C Coupland, H Innes, PC Matthews, C Campbell, ... medRxiv, 2022 | 4 | 2022 |
Impact of the COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus (HBV) infection in the UK. C Campbell, T Wang, DA Smith, O Freeman, T Noble, KA Várnai, S Harris, ... medRxiv, 2021 | 4 | 2021 |
Disparities in care and outcomes for primary liver cancer in England during 2008–2018: a cohort study of 8.52 million primary care population using the QResearch database W Liao, CAC Coupland, H Innes, P Jepsen, PC Matthews, C Campbell, ... EClinicalMedicine 59, 2023 | 3 | 2023 |
Baseline characteristics of a large multi-site chronic HBV electronic health record-based cohort in the UK C Campbell, T Wang, E Barnes, PC Matthews, C Campbell, T Wang The International Liver Congress 2021, 1158, 2021 | 3 | 2021 |
Analysis of primary care electronic health record data of people living with hepatitis B virus: infection and hepatocellular carcinoma risk associated with socio-economic … PCM C. Campbell, T. Wang, I. Gillespie, E. Barnes Public Health 226, 215-227, 2024 | 1 | 2024 |
A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) genotypic resistance in people treated with entecavir or tenofovir SF Lumley, M Delphin, JF Mokaya, CCS Tan, E Martyn, M Anderson, ... medRxiv, 2023.11. 08.23298154, 2023 | 1 | 2023 |
Classification of virologic trajectories during nucleos/tide analogue treatment of hepatitis B virus (HBV) infection T Wang, C Campbell, AJ Stockdale, S Todd, K McIntyre, A Frankland, ... medRxiv, 2023.12. 01.23299288, 2023 | 1 | 2023 |
Where Do Those Data Go? Reuse of screening results from clinical trials to estimate population prevalence of HBV infection in adults in Kilifi, Kenya LO Downs, C Campbell, M Abouyannis, M Otiende, M Kapulu, CW Obiero, ... Journal of Virus Eradication, 100355, 2023 | | 2023 |
Novel serum biomarkers for risk stratification in chronic hepatitis B-what do they bring to the table? L Downs, M Delphin, T Wang, C Campbell, S Lumley, E Waddilove, ... Journal of Hepatology 78, S1060, 2023 | | 2023 |
Distinct virologic trajectories in chronic hepatitis B patients identify heterogeneity in response to nucleotide analogue therapy T Wang, C Campbell, G Roadknight, S Little, A Stockdale, S Todd, ... Journal of Hepatology 78, S1075-S1076, 2023 | | 2023 |